|
| Press Releases |
|
 |
|
| Friday, September 17, 2021 |
|
|
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases |
| SinoMab BioScience Limited (HKEX 3681.HK, "SinoMab") announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. ("Sinovent") today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, "Everest") more info >> |
|
| Monday, January 18, 2021 |
|
|
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the first healthy subject was successfully dosed in the Phase I clinical trial of SN1011 more info >> |
|
| Monday, November 23, 2020 |
|
|
SinoMab Commenced Construction of its China Headquarters |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, July 23, 2020 |
|
|
SinoMab entered into Strategic Collaboration with D2M |
| SinoMab BioScience Limited ("SinoMab" of the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Wednesday, June 10, 2020 |
|
|
SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, January 10, 2020 |
|
|
SinoMab Granted the "Most Popular Newly Listed Company" Award |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen. more info >> |
|
| Wednesday, November 20, 2019 |
|
|
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis. more info >> |
|
| Wednesday, October 30, 2019 |
|
|
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Radisson Announces Additional High-Grade Drill Results and Further Extends New Mineralization Beneath the Historic O'Brien Gold Mine
Jan 6, 2026 20:00 HKT/SGT
|
|
|
Hong Kong Toys & Games Fair leads market innovation, debut 'Pop & Play' pavilion opens to industry and public
Jan 6, 2026 18:50 HKT/SGT
|
|
|
CTF Life Amplifies Ecosystem Synergy
Jan 6, 2026 15:35 HKT/SGT
|
|
|
Mitsubishi Motors to Celebrate "Delica Festival" with Custom Versions of Delica D:5 and Delica Mini at Tokyo Auto Salon 2026
Jan 6, 2026 16:25 JST
|
|
|
Mitsubishi Motors Launches the Xforce in Taiwan
Jan 6, 2026 14:42 JST
|
|
|
">
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
Jan 6, 2026 10:43 JST
|
|
|
Asian Financial Forum kicks off 2026 as region's first major event of 2026 
Jan 6, 2026 04:41 HKT/SGT
|
|
|
Notice on the Establishment of a Special Subsidiary
Jan 5, 2026 21:00 HKT/SGT
|
|
|
TANAKA Announces Executive Appointment
Jan 5, 2026 21:00 HKT/SGT
|
|
|
Asian Financial Forum kicks off 2026 as region's first major event of 2026
Jan 5, 2026 15:39 HKT/SGT
|
|
|
Alpha Growth plc: Alpha Longevity Management Ltd Expands Global Platform with Launch of Alpha Alternative Global Fund and Strengthening of Executive Leadership Team
Jan 5, 2026 16:00 JST
|
|
|
The Tampere city region chose Fujitsu to deliver and develop the area's ICT services
Jan 5, 2026 15:23 JST
|
|
|
AVIA's Coalition Against Piracy Secures New Singapore Court Order Blocking 53 Illegal Streaming Domains
Jan 5, 2026 13:35 HKT/SGT
|
|
|
As Geekplus approaches the unlocking, the major cornerstone investors such as Xiongan Fund commit to holding their shares
Jan 5, 2026 09:46 HKT/SGT
|
|
|
Hong Kong Tech Exhibits Immense Potential at CES 2026 with 61 Tech Companies Ready for Global Markets, Largest-ever Hong Kong Tech Pavilion features 3 Innovation Award-winning game-changers showcasing immense potential to scale
Jan 4, 2026 12:03 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
